


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original): A compound of formula (I):



(I)

wherein:

X is O, CR⁷R⁸, NH or bond;

R¹ and R² are both hydrogen, both optionally substituted (C₁₋₄) alkyl, or are together with the carbon to which they are attached form a (C₃₋₆)cycloalkyl ring or a 4- to 6- membered heterocyclyl ring.

R³ and R⁴ are both hydrogen, both optionally substituted (C₁₋₄) alkyl, or are together with the carbon to which they are attached form a (C₃₋₆)cycloalkyl ring or a 4- to 6- membered heterocyclyl ring;

R⁷ and R⁸ are both hydrogen, both optionally substituted (C₁₋₄) alkyl, or are together with the carbon to which they are attached form a (C₃₋₆)cycloalkyl ring or a 4- to 6- membered heterocyclyl ring;

provided that one pair of R¹ and R², R³ and R⁴, R⁷ and R⁸ are both optionally substituted (C₁₋₄) alkyl, or are together with the carbon to which they are attached form a (C₃₋₆)cycloalkyl ring or a 4- to 6- membered heterocyclyl ring and the remaining groups are hydrogen;

R⁵ is hydrogen, optionally substituted (C₁₋₄) alkyl, or optionally substituted (C₁₋₄)alkylCO;

Ar¹ is an optionally substituted aryl, an optionally substituted mono or bicyclic heteroaryl group containing up to 3 heteroatoms selected from N, O and S;

Ar² represents phenyl or a 5- or 6-membered heterocyclyl group containing up to 3 heteroatoms selected from N, O and S, wherein the phenyl or heterocyclyl group is substituted by R⁶ and further optional substituents; or Ar² represents an optionally substituted bicyclic aromatic or bicyclic heteroaromatic group containing up to 4 heteroatoms selected from N, O and S;

R⁶ represents hydrogen, optionally substituted(C₁₋₄)alkoxy, halo, cyano, optionally substituted(C₁₋₆)alkyl, optionally substituted phenyl, or an optionally substituted 5- or 6-membered heterocyclyl group containing up to 4 heteroatoms selected from N, O and S;

or a pharmaceutically acceptable salt thereof.

2. (Original): A compound according to claim 1 wherein X is CR⁷R⁸.
3. (Currently amended): A compound according to claim 1 ~~or 2~~ wherein R¹, R², R⁷ and R⁸ are hydrogen when R³ and R⁴ are methyl or R³, R⁴, R⁷ and R⁸ are hydrogen when R¹ and R² are methyl.
4. (Currently amended): A compound according to claim 1 ~~any one of claims 1 to 3~~ wherein Ar¹ is pyrimidinyl or pyridinyl.
5. (Original): A compound according to claim 4 wherein the pyrimidinyl or pyridinyl is substituted with halogen.
6. (Original): A compound according to claim 5 wherein the halogen is bromine.
7. (Original): A compound of formula (I) as defined in any one of Examples 1 to 44, or a pharmaceutically acceptable salt of any one thereof.
8. (Currently amended): A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 ~~any one of claims 1 to 7~~, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

9. (Currently amended): A method of treating or preventing diseases or disorders where an antagonist of a human orexin receptor is required, which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) as defined in claim 1 ~~any one of claims 1 to 7~~, or a pharmaceutically acceptable salt thereof.

10. (Currently amended): ~~Use of a compound of formula (I), or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the treatment of~~ The method according to claim 9, wherein said disease or disorder is obesity.

11. (Currently amended): ~~Use of a compound of formula (I), or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the treatment of~~ The method according to claim 9, wherein said disease or disorder is a sleep disorder[[s]].